Publication date: Available online 14 November 2026 Source: Molecular Metabolism Author(s): Simon I. Dreher, Robin Schöler, Katharina S. Zorn, Jens Martin, Jana Kühnle, Kevin Elsner, Imme Behle, Thomas Goj, Lara Ruoff, Kolja Leffek, Alessia Moruzzi, Peter Loskill, Andre Tomalka, Tobias Siebert, Andreas L. Birkenfeld, Andreas Peter, Cora Weigert
Functional primary human 3D skeletal muscle models enable exercise and metabolic research. // Molecular Metabolism. – URL: https://www.sciencedirect.com/science/article/pii/S2212877826001584?dgcid=rss_sd_all
Functional primary human 3D skeletal muscle models enable exercise and metabolic research. Molecular Metabolism. https://www.sciencedirect.com/science/article/pii/S2212877826001584?dgcid=rss_sd_all
“Functional primary human 3D skeletal muscle models enable exercise and metabolic research.” Molecular Metabolism.
@article{article59354,
title = {Functional primary human 3D skeletal muscle models enable exercise and metabolic research},
journal = {Molecular Metabolism},
url = {https://www.sciencedirect.com/science/article/pii/S2212877826001584?dgcid=rss_sd_all}
}
Gene Therapy, Published online: 13 November 2026; doi:10.1038/s41434-026-00658-6 Clinical landscape of gene therapy for rare diseases: a registry-based analysis of clinical trials and FDA-approved products
Human Genome Variation, Published online: 12 November 2026; doi:10.1038/s41439-026-00361-3 Arthrogryposis involves multiple joint contractures present at birth, affecting both upper and lower extremities. This study investigates the...
Gene Therapy, Published online: 10 November 2026; doi:10.1038/s41434-026-00657-7 Perspectives on cell and gene therapy: insights from the 5th China Annual Congress on CGT
Gene Therapy, Published online: 04 November 2026; doi:10.1038/s41434-026-00649-7 High-resolution separation and quantification of dual-AAV drug products by density gradient equilibrium analytical ultracentrifugation
Gene Therapy, Published online: 03 November 2026; doi:10.1038/s41434-026-00656-8 Genotoxic safety and long-term engraftment dynamics of efficient translational CRISPR/Cas9 therapeutics for β-haemoglobinopathies from bench to clinical trials